Sofinnova Investments
VC Fund
Menlo Park, United States
Sofinnova Investments is a VC fund in Menlo Park focused on Biotechnology and Health Care. Sofinnova Ventures has partnered with entrepreneurs to secure initial funding, build successful teams, win key customers, and navigate acquisitions and IPOs. Sofinnova Ventures invests in Life Science and Technology start-ups. Their professionals are seasoned business operators, possessing deep domain and investment expertise. They know how to helpentrepreneurs build successful, global businesses.
- Total investments:
- 221
- Last investment:
- Lead investor:
- 30%
- Fund size:
- $650M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Sofinnova Investments invests in
Stages Sofinnova Investments invests in
Countries Sofinnova Investments invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 14 contacts → | |||
Round size
- Series A
- $7.3M–$115M
- Series B
- $15M–$150M
- Series C
- $15M–$94M
Investment Focus
Industry
- Biotechnology 102 (46%)
- Health Care 64 (29%)
- Pharmaceutical 46 (21%)
- Medical 43 (19%)
- Therapeutics 42 (19%)
Stage
- Series B 51 (23%)
- Series A 45 (20%)
- Series C 32 (14%)
- Funding Round 27 (12%)
- Series D 18 (8%)
Country
- United States 100 (45%)
- France 9 (4%)
- Switzerland 4 (2%)
- United Kingdom 4 (2%)
- The Netherlands 3 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Jakob Dupont
Executive Partner
|
Executive Partner | Total investments: 3 | Find email | |
James Healy
General Partner & President
|
General Partner & President | Total investments: 25 | Find email | |
Jonathan Leff
Executive Partner, Private Equity
|
Executive Partner, Private Equity | Total investments: 3 | Find email | |
Lesley Weber
San Diego Office Manager & EA
|
San Diego Office Manager & EA | Total investments: 0 | Find email | |
Maha Radhakrishnan
Executive Partner
|
Executive Partner | Total investments: 2 | Find email | |
| See all 14 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Expedition Therapeutics
|
Expedition Therapeutics operates as an unincorporated association. | $115M / Series B / Aug 05, 2026 | |
Claris Biotherapeutics
|
Claris Biotherapeutics develops a topical formulation intended to cure corneal wounds, ulcers, and scars. The formulation creates a recombinant hepatocyte growth factor which accelerates the healing process, providing healthcare providers noninvasive therapeutic treatment. | $118M / Series B / Jul 28, 2026 | |
City Therapeutics
|
City Therapeutics is a biopharmaceutical company focusing on engineering next-generation small-interfering RNAs (siRNAs) to enhance RNAi-based therapies. The company develops a pipeline of innovative RNAi therapeutics aimed at addressing various disease indications. City Therapeutics prioritizes improving and expanding RNAi technology to achievebetter patient outcomes. The leadership team includes experienced scientists and industry professionals dedicated to advancing the field of RNA interference. | $99.5M / Series B / Jun 08, 2026 | |
Coultreon Biopharma
|
Coultreon Biopharma is developing best-in-class therapeutics that target clinically validated pathways in immunology and metabolic illnesses.Coultreon Biopharma employs extensive experience in disease biology, drug development, and translational science to identify the optimum treatment approach for addressing underlying illness biology withbest-in-class therapeutics. | $125M / Series A / Apr 28, 2026 | |
Aeovian Pharmaceuticals
|
Aeovian Pharmaceuticals develops and investigates targeted small molecule therapeutics aimed at restoring cellular metabolic quality control to address dysregulated growth and signaling linked to certain rare genetic and age-related conditions. The company’s pipeline centers on compounds that selectively modulate specific biological pathways,including inhibitors designed to influence disease processes associated with neurological dysfunction. Its lead development candidate is a central nervous system-penetrant selective inhibitor being evaluated in clinical trials for refractory seizures related to a genetic disorder, and additional compounds are in earlier stages of investigation for other disease areas. Aeovian Pharmaceuticals also maintains a portfolio of proprietary molecules that engage defined molecular targets to explore potential treatments beyond its program. | $55M / Series B / Dec 16, 2025 | |
|
Expedition Therapeutics
|
Expedition Therapeutics operates as an unincorporated association. | $165M / Series A / Oct 09, 2025 | |
Star Therapeutics
|
Star Therapeutics mission is to develop therapies for as many diseases as possible for millions of patients. | $125M / Series D / Sep 30, 2025 | |
Avenzo Therapeutics
|
Avenzo Therapeutics specializes in the development of oncology therapies for cancer treatment. | $60M / Series B / Sep 04, 2025 | |
ARTBIO
|
ARTBIO is a clinical-stage radiopharmaceutical biotechnology business that is working to create a new class of alpha radioligand medicines. ARTBIO is changing cancer care by creating a new class of alpha radioligand therapeutics (ART) and the ecosystem that supports. | $132M / Series B / Jul 29, 2025 | |
Atsena Therapeutics
|
Atsena Therapeutics is a clinical-stage gene therapy company focused on developing treatments for inherited retinal diseases. Their clinical programs include therapies for X-linked retinoschisis (XLRS) and GUCY2D-associated Leber congenital amaurosis (LCA1). Atsena utilizes an adeno-associated virus (AAV) technology platform, including a novelspreading capsid (AAV.SPR), to target specific retinal conditions. Their ongoing research aims to prevent blindness caused by genetic mutations and is powered by their innovative approach to ocular gene therapy. | $150M / Series C / Apr 02, 2025 | |
| See all 221 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Sofinnova Investments invest in?
Sofinnova Investments invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series B and Series A stage. Most of the 221 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Sofinnova Investments's check size?
Sofinnova Investments typically joins rounds of $7.3M–$115M at Series A, $15M–$150M at Series B and $15M–$94M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Sofinnova Investments participates in.
How do I contact Sofinnova Investments?
Public channels for Sofinnova Investments include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Sofinnova Investments?
The team at Sofinnova Investments includes Jakob Dupont (Executive Partner), James Healy (General Partner & President) and Jonathan Leff (Executive Partner, Private Equity), among 14 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
